Literature DB >> 6555596

New insights taking action.

C Crudi.   

Abstract

Mesh：

Year:  1983        PMID： 6555596

Source DB:  PubMed          Journal:  NITA        ISSN： 0160-3930


× No keyword cloud information.
  1 in total

1.  Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.

Authors:  Fangchao Zheng; Feng Du; Wenmiao Wang; Yongsheng Wang; Ming Li; Jiuda Zhao; Xue Wang; Jian Yue; Jiayu Wang; Zixuan Yang; Ruigang Cai; Fei Ma; Ying Fan; Qing Li; Pin Zhang; Binghe Xu; Peng Yuan
Journal:  Breast Cancer Res Treat       Date:  2021-10-14       Impact factor: 4.872
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.